GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenon Pharmaceuticals Inc (NAS:XENE) » Definitions » 5-Year Yield-on-Cost %

Xenon Pharmaceuticals (Xenon Pharmaceuticals) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 08, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Xenon Pharmaceuticals 5-Year Yield-on-Cost %?

Xenon Pharmaceuticals's yield on cost for the quarter that ended in Mar. 2024 was 0.00.


The historical rank and industry rank for Xenon Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:



XENE's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.87
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Xenon Pharmaceuticals's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Xenon Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenon Pharmaceuticals's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Xenon Pharmaceuticals's 5-Year Yield-on-Cost % falls into.



Xenon Pharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Xenon Pharmaceuticals is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Xenon Pharmaceuticals  (NAS:XENE) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Xenon Pharmaceuticals 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Xenon Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Xenon Pharmaceuticals (Xenon Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
Executives
Gary Patou director
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Gillian Cannon director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Justin D. Gover director SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Patrick Machado director 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Elizabeth A. Garofalo director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Steven Gannon director C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
Simon N. Pimstone director 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Ian Mortimer director, officer: PRESIDENT & CEO C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Christopher John Kenney officer: Chief Medical Officer 200 - 3650 GILMORE WAY, BURNABY, A1 V5G 48W
Andrea Difabio officer: Chief Legal Officer BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Sherry Aulin officer: Chief Financial Officer 200 - 3650 GILMORE WAY, BURNABY A0 V5G 48W
Sherrington Robin officer: SVP Bus. & Corp. Development C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
James R. Empfield officer: SVP, Drug Discovery 200 - 3650 GILMORE WAY, BURNABY A1 VG5 48W
Seggern Christopher Von officer: Chief Commercial Officer 200 - 3650 GILMORE WAY, BURNABY A1 V5G 48W